<p>NewAmsterdam Pharma Company N.V.（NASDAQ:NAMS - 獲取免費報告）在週五上漲了 10.1%，因為加拿大皇家銀行將該股票的目標價從 38.00 美元上調至 39.00 美元。加拿大皇家銀行目前對該股票給予 “跑贏大盤” 的評級。NewAmsterdam Pharma 的交易最高達到 25.09 美元，最後交易價格為 25.28 美元。在午盤交易中，約有 596,445 股成交，較 868,590 股的日均成交量下降了 31%。該股票此前收於 22.96 美元。</p>
<p>其他幾位研究分析師最近也對該股票發佈了報告。Needham &amp; Company LLC 在 6 月 12 日的報告中重申了 “買入” 評級，並設定了 40.00 美元的目標價。花旗集團在 6 月 17 日的研究報告中開始覆蓋 NewAmsterdam Pharma 的股票，給予 “買入” 評級和 42.00 美元的目標價。Cantor Fitzgerald 在 6 月 4 日的研究報告中開始覆蓋 NewAmsterdam Pharma 的股票，設定了 “增持” 評級和 42.00 美元的目標價。高盛集團在 7 月 17 日的研究報告中開始覆蓋 NewAmsterdam Pharma 的股票，設定了 “中性” 評級和 27.00 美元的目標價。最後，Wall Street Zen 在 7 月 5 日的報告中將 NewAmsterdam Pharma 的評級從 “賣出” 上調至 “持有”。兩位分析師對該股票給予 “持有” 評級，八位分析師給予 “買入” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 41.20 美元。</p>
<p>獲取 <strong>NewAmsterdam Pharma</strong> 的提醒：</p>
<p><strong>查看我們關於 NAMS 的最新報告</strong></p>
<h2>內部買賣</h2>
<p>在其他新聞中，董事 James N. Topper 在 6 月 16 日的交易中購買了 8,584 股公司的股票。該股票的平均購買成本為每股 19.50 美元，總價值為 167,388.00 美元。完成購買後，該董事直接持有 3,022,153 股公司的股票，價值為 58,931,983.50 美元。這代表着他們持股比例增加了 0.28%。該購買在向證券交易委員會的備案中披露，相關信息可在 SEC 網站上找到。此外，首席運營官 Douglas F. Kling 在 6 月 16 日的交易中出售了 100,000 股公司的股票。該股票的平均售價為 19.29 美元，總交易額為 1,929,000.00 美元。完成出售後，首席運營官持有 44,000 股公司的股票，價值為 848,760 美元。這筆交易代表着他們持股比例減少了 69.44%。該出售的披露信息可以在此找到。在上個季度，內部人士購買了價值 236,839 美元的 12,364 股公司股票，並出售了價值 4,025,887 美元的 198,612 股股票。目前，內部人士持有 20.84% 的股票。</p>
<h2>機構投資者對 NewAmsterdam Pharma 的看法</h2>
<p>大型投資者最近調整了對該公司的持股。Deerfield Management Company L.P. Series C 在第四季度將其在 NewAmsterdam Pharma 的持股增加了 378.4%。Deerfield Management Company L.P. Series C 現在擁有 4,314,340 股公司的股票，價值為 110,879,000 美元，在此期間又購買了 3,412,590 股。Frazier Life Sciences Management L.P.在第四季度將其在 NewAmsterdam Pharma 的持股增加了 23.8%。Frazier Life Sciences Management L.P.現在擁有 15,916,418 股公司的股票，價值為 409,052,000 美元，在上個季度又購買了 3,061,224 股。Wellington Management Group LLP 在第四季度將其在 NewAmsterdam Pharma 的持股增加了 2,410.4%。Wellington Management Group LLP 現在擁有 2,315,123 股公司的股票，價值為 59,499,000 美元，在此期間又收購了 2,222,900 股。Capital International Investors 在第四季度收購了價值約 53,007,000 美元的 NewAmsterdam Pharma 新股份。最後，RA Capital Management L.P.在第一季度將其在 NewAmsterdam Pharma 的持股增加了 14.6%。RA Capital Management L.P.現在擁有 10,138,938 股公司的股票，價值為 207,544,000 美元，在此期間又購買了 1,293,938 股。對沖基金和其他機構投資者持有該公司 89.89% 的股票。</p>
<h2>NewAmsterdam Pharma 上漲 11.5%</h2>
<p>該公司的市值為 28.8 億美元，市盈率為-15.61，貝塔值為-0.02。該股票的 50 日移動平均價格為 20.58 美元，200 日移動平均價格為 20.01 美元。</p>
<p>NewAmsterdam Pharma（NASDAQ:NAMS - 獲取免費報告）在 8 月 6 日星期三最後發佈了季度收益數據。該公司報告本季度每股收益為（0.15 美元），超出市場共識預期的（0.52 美元）0.37 美元。該公司的季度收入為 1915 萬美元，而分析師預期為 144 萬美元。NewAmsterdam Pharma 的股本回報率為負的 28.78%，淨利潤率為負的 259.07%。分析師預計 NewAmsterdam Pharma Company N.V.在當前年度的每股收益將為-1.75。</p>
<h2>NewAmsterdam Pharma 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>NewAmsterdam Pharma Company N.V.是一家晚期生物製藥公司，開發旨在改善代謝疾病患者護理的療法。該公司正在開發 obicetrapib，這是一種口服低劑量的膽固醇酯轉移蛋白（CETP）抑制劑，目前正在進行多項臨牀試驗，作為單藥治療和與依澤替米貝聯合治療降低 LDL-C 以應對心血管疾病。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而非 NewAmsterdam Pharma</li>
<li>投資股票有不同類型</li>
<li>為什麼 Axon 的 16% 激增預示着公共安全科技的新紀元</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>DraftKings 發佈創紀錄的季度業績，瞄準盈利</li>
<li>股票交易：相對強弱指數（RSI）及其用途</li>
<li>亞馬遜對 IonQ 進行股權投資——有潛在的上漲空間嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 NewAmsterdam Pharma 嗎？</h2>
<p>在考慮 NewAmsterdam Pharma 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 NewAmsterdam Pharma 並不在名單上。</p>
<p>雖然 NewAmsterdam Pharma 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NAMS

<p>NewAmsterdam Pharma（納斯達克代碼：NAMS）股價上漲 10.1%，因加拿大皇家銀行將其目標價從 38 美元上調至 39 美元，並維持 “跑贏大盤” 評級。該股票交易價格為 25.28 美元，交易量下降 31%。其他分析師也發佈了積極評級，市場共識目標價為 41.20 美元。內部交易方面，一名董事購買了股票，而首席運營官則出售了大量股份。機構投資者持有該股票的 89.89%，公司報告的季度每股收益為（0.15 美元），超出預期</p>

<p>NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) rose 10.1% on Friday after Royal Bank Of Canada raised their price target on the stock from $38.00 to $39.00. Royal Bank Of Canada currently has an outperform rating on the stock. NewAmsterdam Pharma traded as high as $25.09 and last traded at $25.28. Approximately 596,445 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 868,590 shares. The stock had previously closed at $22.96.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma Company N.V.（NASDAQ:NAMS - 獲取免費報告）在週五上漲了 10.1%，因為加拿大皇家銀行將該股票的目標價從 38.00 美元上調至 39.00 美元。加拿大皇家銀行目前對該股票給予 “跑贏大盤” 的評級。NewAmsterdam Pharma 的交易最高達到 25.09 美元，最後交易價格為 25.28 美元。在午盤交易中，約有 596,445 股成交，較 868,590 股的日均成交量下降了 31%。該股票此前收於 22.96 美元。</p>
</div><p>Several other research analysts also recently issued reports on the stock. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Citigroup began coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 17th. They issued a &#34;buy&#34; rating and a $42.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an &#34;overweight&#34; rating and a $42.00 target price on the stock. The Goldman Sachs Group began coverage on shares of NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a &#34;neutral&#34; rating and a $27.00 target price for the company. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, July 5th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $41.20.</p>
<div class="lb-trans"><p>其他幾位研究分析師最近也對該股票發佈了報告。Needham &amp; Company LLC 在 6 月 12 日的報告中重申了 “買入” 評級，並設定了 40.00 美元的目標價。花旗集團在 6 月 17 日的研究報告中開始覆蓋 NewAmsterdam Pharma 的股票，給予 “買入” 評級和 42.00 美元的目標價。Cantor Fitzgerald 在 6 月 4 日的研究報告中開始覆蓋 NewAmsterdam Pharma 的股票，設定了 “增持” 評級和 42.00 美元的目標價。高盛集團在 7 月 17 日的研究報告中開始覆蓋 NewAmsterdam Pharma 的股票，設定了 “中性” 評級和 27.00 美元的目標價。最後，Wall Street Zen 在 7 月 5 日的報告中將 NewAmsterdam Pharma 的評級從 “賣出” 上調至 “持有”。兩位分析師對該股票給予 “持有” 評級，八位分析師給予 “買入” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 41.20 美元。</p>
</div><p>Get <strong>NewAmsterdam Pharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>NewAmsterdam Pharma</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Report on NAMS</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 NAMS 的最新報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, Director James N. Topper acquired 8,584 shares of the company's stock in a transaction on Monday, June 16th. The stock was bought at an average cost of $19.50 per share, with a total value of $167,388.00. Following the completion of the purchase, the director directly owned 3,022,153 shares of the company's stock, valued at $58,931,983.50. This represents a 0.28% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, COO Douglas F. Kling sold 100,000 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the completion of the sale, the chief operating officer owned 44,000 shares of the company's stock, valued at $848,760. This trade represents a 69.44% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders bought 12,364 shares of company stock valued at $236,839 and sold 198,612 shares valued at $4,025,887. 20.84% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 James N. Topper 在 6 月 16 日的交易中購買了 8,584 股公司的股票。該股票的平均購買成本為每股 19.50 美元，總價值為 167,388.00 美元。完成購買後，該董事直接持有 3,022,153 股公司的股票，價值為 58,931,983.50 美元。這代表着他們持股比例增加了 0.28%。該購買在向證券交易委員會的備案中披露，相關信息可在 SEC 網站上找到。此外，首席運營官 Douglas F. Kling 在 6 月 16 日的交易中出售了 100,000 股公司的股票。該股票的平均售價為 19.29 美元，總交易額為 1,929,000.00 美元。完成出售後，首席運營官持有 44,000 股公司的股票，價值為 848,760 美元。這筆交易代表着他們持股比例減少了 69.44%。該出售的披露信息可以在此找到。在上個季度，內部人士購買了價值 236,839 美元的 12,364 股公司股票，並出售了價值 4,025,887 美元的 198,612 股股票。目前，內部人士持有 20.84% 的股票。</p>
</div><h2>Institutional Investors Weigh In On NewAmsterdam Pharma</h2>
<div class="lb-trans"><h2>機構投資者對 NewAmsterdam Pharma 的看法</h2>
</div><p>Large investors have recently modified their holdings of the business. Deerfield Management Company L.P. Series C increased its stake in NewAmsterdam Pharma by 378.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock worth $110,879,000 after buying an additional 3,412,590 shares during the period. Frazier Life Sciences Management L.P. raised its holdings in shares of NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock valued at $409,052,000 after buying an additional 3,061,224 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after acquiring an additional 2,222,900 shares during the period. Capital International Investors acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $53,007,000. Finally, RA Capital Management L.P. grew its stake in shares of NewAmsterdam Pharma by 14.6% during the 1st quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock worth $207,544,000 after purchasing an additional 1,293,938 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該公司的持股。Deerfield Management Company L.P. Series C 在第四季度將其在 NewAmsterdam Pharma 的持股增加了 378.4%。Deerfield Management Company L.P. Series C 現在擁有 4,314,340 股公司的股票，價值為 110,879,000 美元，在此期間又購買了 3,412,590 股。Frazier Life Sciences Management L.P.在第四季度將其在 NewAmsterdam Pharma 的持股增加了 23.8%。Frazier Life Sciences Management L.P.現在擁有 15,916,418 股公司的股票，價值為 409,052,000 美元，在上個季度又購買了 3,061,224 股。Wellington Management Group LLP 在第四季度將其在 NewAmsterdam Pharma 的持股增加了 2,410.4%。Wellington Management Group LLP 現在擁有 2,315,123 股公司的股票，價值為 59,499,000 美元，在此期間又收購了 2,222,900 股。Capital International Investors 在第四季度收購了價值約 53,007,000 美元的 NewAmsterdam Pharma 新股份。最後，RA Capital Management L.P.在第一季度將其在 NewAmsterdam Pharma 的持股增加了 14.6%。RA Capital Management L.P.現在擁有 10,138,938 股公司的股票，價值為 207,544,000 美元，在此期間又購買了 1,293,938 股。對沖基金和其他機構投資者持有該公司 89.89% 的股票。</p>
</div><h2>NewAmsterdam Pharma Trading Up 11.5%</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 上漲 11.5%</h2>
</div><p>The firm has a market capitalization of $2.88 billion, a PE ratio of -15.61 and a beta of -0.02. The stock's 50 day moving average price is $20.58 and its two-hundred day moving average price is $20.01.</p>
<div class="lb-trans"><p>該公司的市值為 28.8 億美元，市盈率為-15.61，貝塔值為-0.02。該股票的 50 日移動平均價格為 20.58 美元，200 日移動平均價格為 20.01 美元。</p>
</div><p>NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.37. The company had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 28.78% and a negative net margin of 259.07%. Analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma（NASDAQ:NAMS - 獲取免費報告）在 8 月 6 日星期三最後發佈了季度收益數據。該公司報告本季度每股收益為（0.15 美元），超出市場共識預期的（0.52 美元）0.37 美元。該公司的季度收入為 1915 萬美元，而分析師預期為 144 萬美元。NewAmsterdam Pharma 的股本回報率為負的 28.78%，淨利潤率為負的 259.07%。分析師預計 NewAmsterdam Pharma Company N.V.在當前年度的每股收益將為-1.75。</p>
</div><h2>NewAmsterdam Pharma Company Profile</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma Company N.V.是一家晚期生物製藥公司，開發旨在改善代謝疾病患者護理的療法。該公司正在開發 obicetrapib，這是一種口服低劑量的膽固醇酯轉移蛋白（CETP）抑制劑，目前正在進行多項臨牀試驗，作為單藥治療和與依澤替米貝聯合治療降低 LDL-C 以應對心血管疾病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than NewAmsterdam Pharma</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Amazon Takes an Equity Stake in IonQ—Any Upside Potential?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 NewAmsterdam Pharma</li>
<li>投資股票有不同類型</li>
<li>為什麼 Axon 的 16% 激增預示着公共安全科技的新紀元</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>DraftKings 發佈創紀錄的季度業績，瞄準盈利</li>
<li>股票交易：相對強弱指數（RSI）及其用途</li>
<li>亞馬遜對 IonQ 進行股權投資——有潛在的上漲空間嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in NewAmsterdam Pharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 NewAmsterdam Pharma 嗎？</h2>
</div><p>Before you consider NewAmsterdam Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 NewAmsterdam Pharma 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 NewAmsterdam Pharma 並不在名單上。</p>
</div><p>While NewAmsterdam Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 NewAmsterdam Pharma 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

NewAmsterdam Pharma（NASDAQ:NAMS）在分析師上調評級後股價上漲 10.1%